NDAORAL-28TABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 1/80 28 is an oral combined hormonal contraceptive containing mestranol (estrogen) and norethindrone (progestin) in a 28-day tablet pack. It prevents pregnancy by suppressing ovulation and altering cervical mucus and endometrial conditions. This product is in pre-launch stage, indicating it has not yet been commercially available.
Pre-Launch
Pre-launch status suggests the commercial team is in launch planning phase; team size and resources will depend on Johnson & Johnson's contraceptive portfolio strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This pre-launch contraceptive product offers early-career opportunity in launch planning, regulatory navigation, and commercial strategy within Johnson & Johnson's women's health portfolio. Working on ORTHO-NOVUM 1/80 28 positions professionals at the front end of product commercialization, though long-term career growth depends on market adoption in a saturated, generic-dominated contraceptive category.
Brand Manager
Worked on ORTHO-NOVUM 1/80 28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.